Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Tiede

Showing results (111-120 of 122) with videos related to

Pageof 13
Sort By:
Hemasphere|June 12, 2023
Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice GuidanceRoger E G Schutgens, Victor Jimenez-Yuste, Miguel Escobar, et al.
Thrombosis and Haemostasis|March 11, 2008
Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situationsAndreas Tiede, R Campbell Tait, Don W Shaffer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 21, 2020
Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diaryAndreas Tiede, Santiago Bonanad, Amparo Santamaria, et al.
The Lancet. Haematology|October 20, 2023
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 studyAndreas Tiede, Christina Hart, Paul Knöbl, et al.
Frontiers in Immunology|May 27, 2022
Insights Into Immunothrombotic Mechanisms in Acute Stroke due to Vaccine-Induced Immune Thrombotic ThrombocytopeniaNicole de Buhr, Tristan Baumann, Christopher Werlein, et al.
Blood|December 20, 2014
Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 studyAndreas Tiede, Robert Klamroth, Rüdiger E Scharf, et al.
Journal of Thrombosis and Haemostasis : JTH|February 15, 2023
von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPSMaria Teresa Pagliari, Ulrich Budde, Luciano Baronciani, et al.
Journal of Thrombosis and Haemostasis : JTH|January 29, 2022
Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS studyMaria Teresa Pagliari, Frits R Rosendaal, Minoo Ahmadinejad, et al.
Blood Advances|August 5, 2021
Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPSLuciano Baronciani, Ian Peake, Reinhard Schneppenheim, et al.
Journal of Thrombosis and Haemostasis : JTH|May 8, 2020
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional studyAlberto Tosetto, Zahra Badiee, Mohammad-Reza Baghaipour, et al.
Pageof 13

Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
Hemasphere|June 12, 2023
Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice GuidanceRoger E G Schutgens, Victor Jimenez-Yuste, Miguel Escobar, et al.
Thrombosis and Haemostasis|March 11, 2008
Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situationsAndreas Tiede, R Campbell Tait, Don W Shaffer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 21, 2020
Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diaryAndreas Tiede, Santiago Bonanad, Amparo Santamaria, et al.
The Lancet. Haematology|October 20, 2023
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 studyAndreas Tiede, Christina Hart, Paul Knöbl, et al.
Frontiers in Immunology|May 27, 2022
Insights Into Immunothrombotic Mechanisms in Acute Stroke due to Vaccine-Induced Immune Thrombotic ThrombocytopeniaNicole de Buhr, Tristan Baumann, Christopher Werlein, et al.
Blood|December 20, 2014
Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 studyAndreas Tiede, Robert Klamroth, Rüdiger E Scharf, et al.
Journal of Thrombosis and Haemostasis : JTH|February 15, 2023
von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPSMaria Teresa Pagliari, Ulrich Budde, Luciano Baronciani, et al.
Journal of Thrombosis and Haemostasis : JTH|January 29, 2022
Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS studyMaria Teresa Pagliari, Frits R Rosendaal, Minoo Ahmadinejad, et al.
Blood Advances|August 5, 2021
Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPSLuciano Baronciani, Ian Peake, Reinhard Schneppenheim, et al.
Journal of Thrombosis and Haemostasis : JTH|May 8, 2020
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional studyAlberto Tosetto, Zahra Badiee, Mohammad-Reza Baghaipour, et al.
Pageof 13